Wednesday, November 4, 2026Eastern Time · Updated through the dayRSS

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Novo still aims for US approval of CagriSema around year-end

MH

By Maren Holt · Senior Reporter, GLP-1

Nov 4 08:04 ETSource: MedWatch

From the source

Novo still aims for US approval of CagriSema around year-end

Read at medwatch.com

Source URL https://medwatch.com/News/Pharma___Biotech/article19800920.ece

Prescribed peptides from $99/moSee all →